|
|
|
|
Mucci A. Vignapiano A. Bitter I. Austin S.F., Delouched C., Dollfus S., Erfurth A., Fleischhacker W.W., Giordano G.M., Gladyshev I., Glenthøj B., Gütter K., AlexHoferh, Jan Hubenákˇm, Stefan Kaisern, Libiger J., Melle I., Nielsen M., Papsuev O., Rybakowski J.K., Sachsq G., Üçokr A., Wojciakp P., Galderisi S.
|
|
|
European Neuropsychopharmacology
|
|
|
Negative symptoms represent an unmet need of treatment in schizophrenia. Although a consensus exists on negative symptom construct, and second generation assessment instruments reflecting the consensus are available, studies still rely upon old assessment instruments, that do not reflect recent conceptualizations and might limit progress in the search for effective treatments. This is often the case in the European context, where one of the challenges encountered in designing large studies is the availability of validated instruments in the many languages of the continent. To address this challenge and promote sound research on negative symptoms in Europe, the ECNP Schizophrenia Network coordinated a large multicenter, multinational validation study of the Brief Negative Symptom Scale (BNSS). Clinically-stable subjects with schizophrenia (SCZ, N = 249) were recruited from 10 European Countries.
|
|
Файл скачали: 33
Просмотров публикации: 48
|
|
|
|
Скачать файл
